Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Results of Operations and Financial Condition

Item2.02

Although it has not finalized its full financial results for the
fourth quarter and fiscal year ended December31, 2016, the
Company announced on January9, 2017, that it expects to report
that it had approximately $92.1million in cash and investments
(unaudited) as of December31, 2016.

The information contained in Item2.02 of this Form8-K is
unaudited and preliminary, and does not present all information
necessary for an understanding of the Companys financial
condition as of December31, 2016 and its results of operations
for the three months and year ended December31, 2016. The audit
of the Companys consolidated financial statements for the year
ended December31, 2016 is ongoing and could result in changes to
the information set forth above.

The information in this Item2.02 shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

On January9, 2017, the Company issued a press release announcing
its 2017 business goals and financial guidance. The full text of
this press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference. The
information contained on the websites referenced in the press
release is not incorporated herein.

About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Recent Trading Information

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) closed its last trading session down -0.05 at 1.41 with 779,350 shares trading hands.